Results 191 to 200 of about 103,961 (275)

Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysis

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Immunosuppressive disease was associated with reduced overall survival, while anticoagulant use was linked to prolonged progression‐free survival in advanced cutaneous squamous cell carcinoma treated with immune checkpoint inhibitors. Host‐related factors may modulate immunotherapy efficacy and warrant prospective validation.
Glenn Geidel   +27 more
wiley   +1 more source

Systemic Therapy for Advanced Hepatocellular Carcinoma in 2026: Current Standard‐of‐Care and Emerging Therapeutic Strategies

open access: yesJournal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, accounting for up to 80% of all cases. Most patients present at an advanced stage and are unsuitable for curative treatments. In the past 5 years, immunotherapy combination has superseded tyrosine kinase inhibitors (TKI) as the standard first‐line therapy for ...
Landon L. Chan   +2 more
wiley   +1 more source

Evidence of Cardiotoxic Immune Activation by Triple Immune Checkpoint Blockade: A Translational Alert for Clinical Surveillance in Patients With Cancer. [PDF]

open access: yesJ Cardiovasc Pharmacol
Quagliariello V   +21 more
europepmc   +1 more source

Chronic rhinosinusitis during immune checkpoint inhibition in melanoma patients

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Yenny Angela   +3 more
wiley   +1 more source

Intrahepatic Cholangiocarcinoma: Epidemiological Trends, Risk Factors, Diagnostic Challenges, and Advances in Personalized Therapy—A Comprehensive Review

open access: yesJournal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Intrahepatic cholangiocarcinoma (iCCA) ranks as the second most common primary liver cancer, compared to about 20% of cases. Its global incidence has climbed over the past four decades, yet early detection remains indefinable due to its asymptomatic nature. Five‐year survival rate of approximately is under 10%.
Yaqoob Muhammad   +10 more
wiley   +1 more source

Author Correction: First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort IKF-AIO-MOONLIGHT trial. [PDF]

open access: yesNat Commun
Lorenzen S   +20 more
europepmc   +1 more source

Immune, molecular and genetic profiles of gastric signet ring cell carcinoma: Recent progress and future challenges

open access: yesInternational Journal of Cancer, Volume 159, Issue 1, Page 11-29, 1 July 2026.
Abstract Gastric signet ring cell carcinoma (GSRCC) is a special type of gastric cancer common in young women. Diffuse gastric cancer (DGC) begins with intramucosal lesions comprising differentiated GSRCC cells. Genetically, GSRCC and DGC are clonally identical, with their morphology influenced by extracellular Wnt signaling.
Qian Wang   +5 more
wiley   +1 more source

Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology in patients with advanced non-small-cell lung cancer (FRACTION-Lung). [PDF]

open access: yesESMO Open
He K   +19 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy